<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02620332</url>
  </required_header>
  <id_info>
    <org_study_id>MultiPep001</org_study_id>
    <nct_id>NCT02620332</nct_id>
  </id_info>
  <brief_title>Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)</brief_title>
  <acronym>MultiPepT1De</acronym>
  <official_title>Multiple Islet Peptide Administration in Type 1 Diabetes (MultiPepT1De)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>King's College London</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Guy's and St Thomas' NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>King's College London</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Type 1 diabetes is an autoimmune disease in which the insulin secreting βcells of the
      pancreas are destroyed such that the patient is reliant on injection of insulin to adequately
      control blood glucose levels for the remainder of his/her life. The autoimmune process
      targets proteins in beta-cells which are termed autoantigens. This is a Phase 1 study using a
      novel investigational medicinal product (IMP) known as MultiPepT1De in a study of safety and
      tolerability of administration in patients with recent onset Type 1 diabetes. MultiPepT1De is
      a mixture of peptides from islet auto antigens. The mixture has been designed to induce or
      restore immunological tolerance to the beta-cell and thus control or limit autoimmunity to
      protect beta-cells
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Recent onset type 1 diabetes patients will be randomized into 4 groups of 6 subjects and each
      group will receive 6 injections of either placebo, low, medium or high dose of IMP; each
      injection is intradermal and spaced 1 month apart.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">February 2017</completion_date>
  <primary_completion_date type="Anticipated">February 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of MultiPepT1De safety profile</measure>
    <time_frame>Every 28 days for 147 days</time_frame>
    <description>Safety assessed through measurement and comparison of any reactions or hypersensitivity to MultipepT1De injection vs placebo. Number of adverse events will also be compared between groups with the addition of safety monitoring blood tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of residual beta cell function and markers of metabolic control</measure>
    <time_frame>24 weeks versus baseline</time_frame>
    <description>Measured by a change in stimulated C-peptide production, daily insulin usage, glycated haemoglobin levels and amplitude of glucose excursions from baseline and between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of T lymphocyte immune response to islet cell antigens</measure>
    <time_frame>24 weeks versus 12 weeks</time_frame>
    <description>Comparison of changes in antigen specific T lymphocyte responses longitudinally following peptide treatment and versus placebo.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Placebo injection</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Water for injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MultiPepT1De injection low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MultiPepT1De injection medium dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MultiPepT1De injection high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mix of peptides administered once a month over a period of 20 weeks (6 injections in total)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MultiPepT1De injection</intervention_name>
    <description>A mix of peptides</description>
    <arm_group_label>MultiPepT1De injection low dose</arm_group_label>
    <arm_group_label>MultiPepT1De injection medium dose</arm_group_label>
    <arm_group_label>MultiPepT1De injection high dose</arm_group_label>
    <other_name>Multipeptide injection</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Water for injection</description>
    <arm_group_label>Placebo injection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of Type 1 diabetes

          -  Age 18-45 years

          -  Maximum of 4 years from diagnosis

          -  Evidence of ≥1 autoantibody against β-cell autoantigens

          -  Possession of the HLA-DR4 (DRB1*0401) genotype

          -  Residual β-cell function (peak C-peptide &gt;200)

        Exclusion Criteria:

          -  Females who are pregnant, breast-feeding or not using adequate forms of contraception.

          -  Use of β-cell stimulants, immunosuppressive or immunomodulatory therapies, including
             systemic steroids within 1 month prior to randomization, any monoclonal antibody
             therapy given for any indication and any antigen-specific
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jake Powrie, MD FRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guy's and St Thomas' NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Peakman, MBBS PhD</last_name>
    <role>Study Director</role>
    <affiliation>King's College London</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Rhanya Chaabane</last_name>
    <phone>00 44 071 88 7188</phone>
    <phone_ext>88472</phone_ext>
    <email>multipeptide@gstt.nhs.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>Guy's Hospital</name>
      <address>
        <city>London</city>
        <zip>SE1 9RT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rhanya Chaabane</last_name>
      <phone>00 44 7188 7188</phone>
      <phone_ext>88472</phone_ext>
      <email>multipeptide@gstt.nhs.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2015</study_first_submitted>
  <study_first_submitted_qc>December 1, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 3, 2015</study_first_posted>
  <last_update_submitted>December 1, 2015</last_update_submitted>
  <last_update_submitted_qc>December 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

